Search

Your search keyword '"Pui, Ching‐Hon"' showing total 3,513 results
Start Over Author "Pui, Ching‐Hon"
3,513 results on '"Pui, Ching‐Hon"'

1. Genomic profiling of circulating tumor DNA for childhood cancers

Author

Lei, Shaohua, Jia, Sujuan, Takalkar, Sunitha, Chang, Ti-Cheng, Ma, Xiaotu, Szlachta, Karol, Xu, Ke, Cheng, Zhongshan, Hui, Yawei, Koo, Selene C., Mead, Paul E., Gao, Qingsong, Kumar, Priyadarshini, Bailey, Colin P., Sunny, Jobin, Pappo, Alberto S., Federico, Sara M., Robinson, Giles W., Gajjar, Amar, Rubnitz, Jeffrey E., Jeha, Sima, Pui, Ching-Hon, Inaba, Hiroto, Wu, Gang, Klco, Jeffery M., Tatevossian, Ruth G., and Mullighan, Charles G.

Published
2024
Full Text
View/download PDF

4. Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment

Author

Bhattarai, Kashi Raj, Mobley, Robert J., Barnett, Kelly R., Ferguson, Daniel C., Hansen, Baranda S., Diedrich, Jonathan D., Bergeron, Brennan P., Yoshimura, Satoshi, Yang, Wenjian, Crews, Kristine R., Manring, Christopher S., Jabbour, Elias, Paietta, Elisabeth, Litzow, Mark R., Kornblau, Steven M., Stock, Wendy, Inaba, Hiroto, Jeha, Sima, Pui, Ching-Hon, Cheng, Cheng, Pruett-Miller, Shondra M., Relling, Mary V., Yang, Jun J., Evans, William E., and Savic, Daniel

Published
2024
Full Text
View/download PDF

6. Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China

Author

Leung, Kam Tong, Cai, Jiaoyang, Liu, Yu, Chan, Kathy Yuen Yee, Shao, Jingbo, Yang, Hui, Hu, Qun, Xue, Yao, Wu, Xuedong, Guo, Xia, Zhai, Xiaowen, Wang, Ningling, Li, Xue, Tian, Xin, Li, Zheng, Xue, Ning, Guo, Yuxia, Wang, Lingzhen, Zou, Yao, Xiao, Peifang, He, Yingyi, Jin, Runming, Tang, Jingyan, Yang, Jun J., Shen, Shuhong, Pui, Ching-Hon, and Li, Chi Kong

Published
2024
Full Text
View/download PDF

7. Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks

Author

Diedrich, Jonathan D., Dong, Qian, Ferguson, Daniel C., Bergeron, Brennan P., Autry, Robert J., Qian, Maoxiang, Yang, Wenjian, Smith, Colton, Papizan, James B., Connelly, Jon P., Hagiwara, Kohei, Crews, Kristine R., Pruett-Miller, Shondra M., Pui, Ching-Hon, Yang, Jun J., Relling, Mary V., Evans, William E., and Savic, Daniel

Published
2024
Full Text
View/download PDF

11. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia

Author

Huang, Xin, Li, Yizhen, Zhang, Jingliao, Yan, Lei, Zhao, Huanbin, Ding, Liang, Bhatara, Sheetal, Yang, Xu, Yoshimura, Satoshi, Yang, Wenjian, Karol, Seth E., Inaba, Hiroto, Mullighan, Charles, Litzow, Mark, Zhu, Xiaofan, Zhang, Yingchi, Stock, Wendy, Jain, Nitin, Jabbour, Elias, Kornblau, Steven M., Konopleva, Marina, Pui, Ching-Hon, Paietta, Elisabeth, Evans, William, Yu, Jiyang, and Yang, Jun J.

Published
2024
Full Text
View/download PDF

13. Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators

Author

Barnett, Kelly R., Mobley, Robert J., Diedrich, Jonathan D., Bergeron, Brennan P., Bhattarai, Kashi Raj, Monovich, Alexander C., Narina, Shilpa, Yang, Wenjian, Crews, Kristine R., Manring, Christopher S., Jabbour, Elias, Paietta, Elisabeth, Litzow, Mark R., Kornblau, Steven M., Stock, Wendy, Inaba, Hiroto, Jeha, Sima, Pui, Ching-Hon, Mullighan, Charles G., Relling, Mary V., Pruett-Miller, Shondra M., Ryan, Russell J.H., Yang, Jun J., Evans, William E., and Savic, Daniel

Published
2023
Full Text
View/download PDF

15. Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

Author

Ohki, Kentaro, Butler, Ellie R., Kiyokawa, Nobutaka, Hirabayashi, Shinsuke, Bergmann, Anke K., Möricke, Anja, Boer, Judith M., Cavé, Hélène, Cazzaniga, Giovanni, Yeoh, Allen Eng Juh, Sanada, Masashi, Imamura, Toshihiko, Inaba, Hiroto, Mullighan, Charles G., Loh, Mignon L., Norén-Nyström, Ulrika, Shih, Lee-Yung, Zaliova, Marketa, Pui, Ching-Hon, Haas, Oskar A., Harrison, Christine J., Moorman, Anthony V., and Manabe, Atsushi

Published
2023
Full Text
View/download PDF

16. Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response

Author

Lee, Shawn H. R., Yang, Wenjian, Gocho, Yoshihiro, John, August, Rowland, Lauren, Smart, Brandon, Williams, Hannah, Maxwell, Dylan, Hunt, Jeremy, Yang, Wentao, Crews, Kristine R., Roberts, Kathryn G., Jeha, Sima, Cheng, Cheng, Karol, Seth E., Relling, Mary V., Rosner, Gary L., Inaba, Hiroto, Mullighan, Charles G., Pui, Ching-Hon, Evans, William E., and Yang, Jun J.

Published
2023
Full Text
View/download PDF

17. Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome–positive acute lymphoblastic leukemia: a case–control study

Author

Cai, Jiaoyang, Liu, Hu, Chen, Yumei, Yu, Jie, Gao, Ju, Jiang, Hua, Zhai, Xiaowen, Ju, Xiuli, Wu, Xuedong, Wang, Ningling, Tian, Xin, Liang, Changda, Fang, Yongjun, Zhou, Fen, Li, Hong, Sun, Lirong, Yang, Liangchun, Guo, Jing, Liu, Aiguo, Li, Chi-kong, Zhu, Yiping, Tang, Jingyan, Yang, Jun J., Shen, Shuhong, Cheng, Cheng, and Pui, Ching-Hon

Published
2023
Full Text
View/download PDF

20. Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia

Author

Karol, Seth E, Cooper, Todd M, Mead, Paul E, Crews, Kristine R, Panetta, John C, Alexander, Thomas B, Taub, Jeffrey W, Lacayo, Norman J, Heym, Kenneth M, Kuo, Dennis J, Schiff, Deborah E, Bhojwani, Deepa, Ge, Yubin, Klco, Jeffery M, Ribeiro, Raul C, Inaba, Hiroto, Pui, Ching‐Hon, and Rubnitz, Jeffrey E

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Hematology, Genetics, Cancer, Pediatric Cancer, Clinical Research, Clinical Trials and Supportive Activities, Rare Diseases, Pediatric, Pediatric Research Initiative, Childhood Leukemia, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Child, Female, Humans, Leukemia, Myeloid, Acute, Male, Neoplasm Recurrence, Local, Panobinostat, Young Adult, acute myeloid leukemia, childhood, relapse, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundNovel therapies are urgently needed for pediatric patients with relapsed acute myeloid leukemia (AML).MethodsTo determine whether the histone deacetylase inhibitor panobinostat could be safely given in combination with intensive chemotherapy, a phase 1 trial was performed in which 17 pediatric patients with relapsed or refractory AML received panobinostat (10, 15, or 20 mg/m2 ) before and in combination with fludarabine and cytarabine.ResultsAll dose levels were tolerated, with no dose-limiting toxicities observed at any dose level. Pharmacokinetic studies demonstrated that exposure to panobinostat was proportional to the dose given, with no associations between pharmacokinetic parameters and age, weight, or body surface area. Among the 9 patients who had sufficient (>2%) circulating blasts on which histone acetylation studies could be performed, 7 demonstrated at least 1.5-fold increases in acetylation. Although no patients had a decrease in circulating blasts after single-agent panobinostat, 8 of the 17 patients (47%), including 5 of the 6 patients treated at dose level 3, achieved complete remission. Among the 8 complete responders, 6 (75%) attained negative minimal residual disease status.ConclusionsPanobinostat can be safely administered with chemotherapy and results in increased blast histone acetylation. This suggests that it should be further studied in AML.

Published
2020

21. Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia

Author

Bergeron, Brennan P., Diedrich, Jonathan D., Zhang, Yang, Barnett, Kelly R., Dong, Qian, Ferguson, Daniel C., Autry, Robert J., Yang, Wenjian, Hansen, Baranda S., Smith, Colton, Crews, Kristine R., Fan, Yiping, Pui, Ching-Hon, Pruett-Miller, Shondra M., Relling, Mary V., Yang, Jun J., Li, Chunliang, Evans, William E., and Savic, Daniel

Published
2022
Full Text
View/download PDF

23. The genomic landscape of pediatric acute lymphoblastic leukemia

Author

Brady, Samuel W., Roberts, Kathryn G., Gu, Zhaohui, Shi, Lei, Pounds, Stanley, Pei, Deqing, Cheng, Cheng, Dai, Yunfeng, Devidas, Meenakshi, Qu, Chunxu, Hill, Ashley N., Payne-Turner, Debbie, Ma, Xiaotu, Iacobucci, Ilaria, Baviskar, Pradyuamna, Wei, Lei, Arunachalam, Sasi, Hagiwara, Kohei, Liu, Yanling, Flasch, Diane A., Liu, Yu, Parker, Matthew, Chen, Xiaolong, Elsayed, Abdelrahman H., Pathak, Omkar, Li, Yongjin, Fan, Yiping, Michael, J. Robert, Rusch, Michael, Wilkinson, Mark R., Foy, Scott, Hedges, Dale J., Newman, Scott, Zhou, Xin, Wang, Jian, Reilly, Colleen, Sioson, Edgar, Rice, Stephen V., Pastor Loyola, Victor, Wu, Gang, Rampersaud, Evadnie, Reshmi, Shalini C., Gastier-Foster, Julie, Guidry Auvil, Jaime M., Gesuwan, Patee, Smith, Malcolm A., Winick, Naomi, Carroll, Andrew J., Heerema, Nyla A., Harvey, Richard C., Willman, Cheryl L., Larsen, Eric, Raetz, Elizabeth A., Borowitz, Michael J., Wood, Brent L., Carroll, William L., Zweidler-McKay, Patrick A., Rabin, Karen R., Mattano, Leonard A., Maloney, Kelly W., Winter, Stuart S., Burke, Michael J., Salzer, Wanda, Dunsmore, Kimberly P., Angiolillo, Anne L., Crews, Kristine R., Downing, James R., Jeha, Sima, Pui, Ching-Hon, Evans, William E., Yang, Jun J., Relling, Mary V., Gerhard, Daniela S., Loh, Mignon L., Hunger, Stephen P., Zhang, Jinghui, and Mullighan, Charles G.

Published
2022
Full Text
View/download PDF

24. Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk.

Author

Vijayakrishnan, Jayaram, Qian, Maoxiang, Studd, James B, Yang, Wenjian, Kinnersley, Ben, Law, Philip J, Broderick, Peter, Raetz, Elizabeth A, Allan, James, Pui, Ching-Hon, Vora, Ajay, Evans, William E, Moorman, Anthony, Yeoh, Allen, Yang, Wentao, Li, Chunliang, Bartram, Claus R, Mullighan, Charles G, Zimmerman, Martin, Hunger, Stephen P, Schrappe, Martin, Relling, Mary V, Stanulla, Martin, Loh, Mignon L, Houlston, Richard S, and Yang, Jun J

Subjects
Humans, Genetic Predisposition to Disease, RNA-Binding Proteins, Oncogene Proteins, Fusion, Risk Factors, Polymorphism, Single Nucleotide, Child, Core Binding Factor Alpha 2 Subunit, bcl-2 Homologous Antagonist-Killer Protein, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Genome-Wide Association Study, Epigenomics, Transcriptome, Oncogene Proteins, Fusion, Polymorphism, Single Nucleotide
Abstract

There is increasing evidence for a strong inherited genetic basis of susceptibility to acute lymphoblastic leukaemia (ALL) in children. To identify new risk variants for B-cell ALL (B-ALL) we conducted a meta-analysis with four GWAS (genome-wide association studies), totalling 5321 cases and 16,666 controls of European descent. We herein describe novel risk loci for B-ALL at 9q21.31 (rs76925697, P = 2.11 × 10-8), for high-hyperdiploid ALL at 5q31.1 (rs886285, P = 1.56 × 10-8) and 6p21.31 (rs210143 in BAK1, P = 2.21 × 10-8), and ETV6-RUNX1 ALL at 17q21.32 (rs10853104 in IGF2BP1, P = 1.82 × 10-8). Particularly notable are the pleiotropic effects of the BAK1 variant on multiple haematological malignancies and specific effects of IGF2BP1 on ETV6-RUNX1 ALL evidenced by both germline and somatic genomic analyses. Integration of GWAS signals with transcriptomic/epigenomic profiling and 3D chromatin interaction data for these leukaemia risk loci suggests deregulation of B-cell development and the cell cycle as central mechanisms governing genetic susceptibility to ALL.

Published
2019

25. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.

Author

Nguyen, Rosa, Wu, Huiyun, Pounds, Stanley, Inaba, Hiroto, Ribeiro, Raul, Cullins, David, Rooney, Barbara, Bell, Teresa, Lacayo, Norman, Heym, Kenneth, Degar, Barbara, Janssen, William, Triplett, Brandon, Pui, Ching-Hon, Leung, Wing, Rubnitz, Jeffrey, and Schiff, Deborah

Subjects
Acute myeloid leukemia, Child, Clinical trial, Natural killer cells, Adolescent, Adoptive Transfer, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Consolidation Chemotherapy, Cyclophosphamide, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Infant, Interleukin-2, Killer Cells, Natural, Leukemia, Myeloid, Acute, Male, Transplantation, Haploidentical, Vidarabine
Abstract

Consolidation therapies for children with intermediate- or high-risk acute myeloid leukemia (AML) are urgently needed to achieve higher cure rates while limiting therapy-related toxicities. We determined if adoptive transfer of natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor (KIR)-human leukocyte antigen (HLA)-mismatched donors may prolong event-free survival in children with intermediate-risk AML who were in first complete remission after chemotherapy. Patients received cyclophosphamide (Day - 7), fludarabine (Days - 6 through - 2), and subcutaneous interleukin-2 (Days - 1, 1, 3, 5, 7, and 9). Purified, unmanipulated NK cells were infused on Day 0, and NK cell chimerism and phenotyping from peripheral blood were performed on Days 7, 14, 21, and 28. As primary endpoint, the event-free survival was compared to a cohort of 55 patients who completed chemotherapy and were in first complete remission but did not receive NK cells. Donor NK cell kinetics were determined as secondary endpoints. Twenty-one patients (median age at diagnosis, 6.0 years [range, 0.1-15.3 years]) received a median of 12.5 × 106 NK cells/kg (range, 3.6-62.2 × 106 cells/kg) without major side effects. All but 3 demonstrated transient engraftment with donor NK cells (median peak donor chimerism, 4% [range, 0-43%]). KIR-HLA-mismatched NK cells expanded in 17 patients (81%) and contracted in 4 (19%). However, adoptive transfer of NK cells did not decrease the cumulative incidence of relapse (0.393 [95% confidence interval: 0.182-0.599] vs. 0.35 [0.209-0.495]; P = .556) and did not improve event-free (60.7 ± 10.9% vs. 69.1 ± 6.8%; P = .553) or overall survival (84.2 ± 8.5% vs. 79.1 ± 6.6%; P = .663) over chemotherapy alone. The lack of benefit may result from insufficient numbers and limited persistence of alloreactive donor NK cells but does not preclude its potential usefulness during other phases of therapy, or in combination with other immunotherapeutic agents. TRIAL REGISTRATION: www.clinicaltrials.gov , NCT00703820 . Registered 24 June 2008.

Published
2019

26. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL

Author

Talleur, Aimee C., Qudeimat, Amr, Métais, Jean-Yves, Langfitt, Deanna, Mamcarz, Ewelina, Crawford, Jeremy Chase, Huang, Sujuan, Cheng, Cheng, Hurley, Caitlin, Madden, Renee, Sharma, Akshay, Suliman, Ali, Srinivasan, Ashok, Velasquez, M. Paulina, Obeng, Esther A., Willis, Catherine, Akel, Salem, Karol, Seth E., Inaba, Hiroto, Bragg, Allison, Zheng, Wenting, Zhou, Sheng M., Schell, Sarah, Tuggle-Brown, MaCal, Cullins, David, Patil, Sagar L, Li, Ying, Thomas, Paul G., Zebley, Caitlin, Youngblood, Benjamin, Pui, Ching-Hon, Lockey, Timothy, Geiger, Terrence L., Meagher, Michael M., Triplett, Brandon M., and Gottschalk, Stephen

Published
2022
Full Text
View/download PDF

27. Sequential Approach to Improve the Molecular Classification of Childhood Acute Lymphoblastic Leukemia

Author

Yu, Chih-Hsiang, Wu, Gang, Chang, Chia-Ching, Jou, Shiann-Tarng, Lu, Meng-Yao, Lin, Kai-Hsin, Chen, Shu-Huey, Wu, Kang-Hsi, Huang, Fang-Liang, Cheng, Chao-Neng, Chang, Hsiu-Hao, Hedges, Dale, Wang, Jinn-Li, Yen, Hsiu-Ju, Li, Meng-Ju, Chou, Shu-Wei, Hung, Chen-Ting, Lin, Ze-Shiang, Lin, Chien-Yu, Chen, Hsuan-Yu, Ni, Yu-Ling, Hsu, Yin-Chen, Lin, Dong-Tsamn, Lin, Shu-Wha, Yang, Jun J., Pui, Ching-Hon, Yu, Sung-Liang, and Yang, Yung-Li

Published
2022
Full Text
View/download PDF

29. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Author

Arber, Daniel A., Orazi, Attilio, Hasserjian, Robert P., Borowitz, Michael J., Calvo, Katherine R., Kvasnicka, Hans-Michael, Wang, Sa A., Bagg, Adam, Barbui, Tiziano, Branford, Susan, Bueso-Ramos, Carlos E., Cortes, Jorge E., Dal Cin, Paola, DiNardo, Courtney D., Dombret, Hervé, Duncavage, Eric J., Ebert, Benjamin L., Estey, Elihu H., Facchetti, Fabio, Foucar, Kathryn, Gangat, Naseema, Gianelli, Umberto, Godley, Lucy A., Gökbuget, Nicola, Gotlib, Jason, Hellström-Lindberg, Eva, Hobbs, Gabriela S., Hoffman, Ronald, Jabbour, Elias J., Kiladjian, Jean-Jacques, Larson, Richard A., Le Beau, Michelle M., Loh, Mignon L.-C., Löwenberg, Bob, Macintyre, Elizabeth, Malcovati, Luca, Mullighan, Charles G., Niemeyer, Charlotte, Odenike, Olatoyosi M., Ogawa, Seishi, Orfao, Alberto, Papaemmanuil, Elli, Passamonti, Francesco, Porkka, Kimmo, Pui, Ching-Hon, Radich, Jerald P., Reiter, Andreas, Rozman, Maria, Rudelius, Martina, Savona, Michael R., Schiffer, Charles A., Schmitt-Graeff, Annette, Shimamura, Akiko, Sierra, Jorge, Stock, Wendy A., Stone, Richard M., Tallman, Martin S., Thiele, Jürgen, Tien, Hwei-Fang, Tzankov, Alexandar, Vannucchi, Alessandro M., Vyas, Paresh, Wei, Andrew H., Weinberg, Olga K., Wierzbowska, Agnieszka, Cazzola, Mario, Döhner, Hartmut, and Tefferi, Ayalew

Published
2022
Full Text
View/download PDF

30. Why do subcutaneous ports get stuck? A case-control study

Author

Crook, Jennifer L., Lu, Zhaohua, Wang, Xiaoqing, Henderson, Nan, Proctor, Kimberly E., Maller, Vinod G., Prajapati, Hasmukh J., Gold, Robert E., Abdelhafeez, Abdelhafeez H., Talbot, Lindsay J., Pui, Ching-Hon, Davidoff, Andrew M., Hoffman, James M., and Murphy, Andrew J.

Published
2022
Full Text
View/download PDF

31. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Author

Kimura, Shunsuke, Montefiori, Lindsey, Iacobucci, Ilaria, Zhao, Yaqi, Gao, Qingsong, Paietta, Elisabeth M., Haferlach, Claudia, Laird, A. Douglas, Mead, Paul E., Gu, Zhaohui, Stock, Wendy, Litzow, Mark, Rowe, Jacob M., Luger, Selina M., Hunger, Stephen P., Ryland, Georgina L., Schmidt, Breon, Ekert, Paul G., Oshlack, Alicia, Grimmond, Sean M., Rehn, Jacqueline, Breen, James, Yeung, David, White, Deborah L., Aldoss, Ibrahim, Jabbour, Elias J., Pui, Ching-Hon, Meggendorfer, Manja, Walter, Wencke, Kern, Wolfgang, Haferlach, Torsten, Brady, Samuel, Zhang, Jinghui, Roberts, Kathryn G., Blombery, Piers, and Mullighan, Charles G.

Published
2022
Full Text
View/download PDF

32. Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia

Author

Ferguson, Daniel C., McCorkle, J. Robert, Barnett, Kelly R., Bonten, Erik J., Bergeron, Brennan P., Bhattarai, Kashi Raj, Yang, Wenjian, Smith, Colton, Hansen, Baranda S., Bajpai, Richa, Dong, Qian, Autry, Robert J., Gocho, Yoshihiro, Diedrich, Jonathan D., Crews, Kristine R., Pruett-Miller, Shondra M., Roberts, Kathryn G., Stock, Wendy, Mullighan, Charles G., Inaba, Hiroto, Jeha, Sima, Pui, Ching-Hon, Yang, Jun J., Relling, Mary V., Evans, William E., and Savic, Daniel

Published
2022
Full Text
View/download PDF

34. Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing.

Author

Hu, Zhongbo, Escalera‐Joy, Andrea M., Ashcraft, Emily, Acharya, Rushil, Jeha, Sima, Cheng, Cheng, and Pui, Ching‐Hon

Subjects
ACUTE kidney failure, EXANTHEMA, CHILDREN'S hospitals, LYMPHOBLASTIC leukemia, METHOTREXATE, MUCOSITIS
Abstract

Background: Oral mucositis affects about 20% of children undergoing high‐dose methotrexate (HDMTX) for acute lymphoblastic leukemia (ALL), despite existing management strategies. Personalized HDMTX dosing, adjusted by pharmacokinetics and leukemia risk, has reduced mucositis incidence, but variations still occur with similar 24‐h methotrexate levels. Methods: This retrospective study investigated risk factors for oral mucositis under individualized methotrexate protocols. Data from patients with ≥ Grade 2 oral mucositis (CTCAE v4.0) were analyzed from the St. Jude Children's Research Hospital total 16 trial. A 1:1 case–control matching method considered age, sex, risk classification, immunophenotype, and methotrexate course. McNemar's, Bowker's symmetry, and Wilcoxon signed‐rank tests were used for statistical analyses. Risk factors for recurrent mucositis were identified in a case‐only analysis. Results: The study found significant associations between methotrexate‐induced mucositis and new‐onset skin rashes (p = 0.0027), fever (p = 0.0016), neutropenic fever (p = 0.0008), lower absolute neutrophil count (p < 0.0001), acute kidney injury (AKI) (p = 0.0164), delayed methotrexate clearance (p = 0.0133), and higher 42‐h methotrexate levels (p = 0.0179). In the standard/high‐risk group, mercaptopurine dose was also linked to mucositis (p = 0.0495). Multivariable analysis showed that skin rashes (OR 6.5, p = 0.0016), fever (OR 2.8, p = 0.009), and neutropenia (OR 2.3, p = 0.0106) were independent risk factors for mucositis. Female sex (OR 7.12, p = 0.015) and AKI (OR 3.819, p = 0.037) were associated with recurrent mucositis. Conclusions: Fever, skin rashes, AKI, delayed methotrexate clearance, and higher 42‐h methotrexate levels were key risk factors for HDMTX‐induced oral mucositis. Skin rashes, fever, and neutropenia were independent predictors, while female sex and AKI were linked to recurrent mucositis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation

Author

Yang, Hongbo, Zhang, Hui, Luan, Yu, Liu, Tingting, Yang, Wentao, Roberts, Kathryn G., Qian, Mao-xiang, Zhang, Bo, Yang, Wenjian, Perez-Andreu, Virginia, Xu, Jie, Iyyanki, Sriranga, Kuang, Da, Stasiak, Lena A., Reshmi, Shalini C., Gastier-Foster, Julie, Smith, Colton, Pui, Ching-Hon, Evans, William E., Hunger, Stephen P., Platanias, Leonidas C., Relling, Mary V., Mullighan, Charles G., Loh, Mignon L., Yue, Feng, and Yang, Jun J.

Published
2022
Full Text
View/download PDF

39. Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks

Author

Diedrich, Jonathan D., Dong, Qian, Ferguson, Daniel C., Bergeron, Brennan P., Autry, Robert J., Qian, Maoxiang, Yang, Wenjian, Smith, Colton, Papizan, James B., Connelly, Jon P., Hagiwara, Kohei, Crews, Kristine R., Pruett-Miller, Shondra M., Pui, Ching-Hon, Yang, Jun J., Relling, Mary V., Evans, William E., and Savic, Daniel

Published
2021
Full Text
View/download PDF

40. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group

Author

Hirabayashi, Shinsuke, Butler, Ellie R., Ohki, Kentaro, Kiyokawa, Nobutaka, Bergmann, Anke K., Möricke, Anja, Boer, Judith M., Cavé, Hélène, Cazzaniga, Giovanni, Yeoh, Allen Eng Juh, Sanada, Masashi, Imamura, Toshihiko, Inaba, Hiroto, Mullighan, Charles, Loh, Mignon L., Norén-Nyström, Ulrika, Pastorczak, Agata, Shih, Lee-Yung, Zaliova, Marketa, Pui, Ching-Hon, Haas, Oskar A., Harrison, Christine J., Moorman, Anthony V., and Manabe, Atsushi

Published
2021
Full Text
View/download PDF

42. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial

Author

Yang, Wenyu, Cai, Jiaoyang, Shen, Shuhong, Gao, Ju, Yu, Jie, Hu, Shaoyan, Jiang, Hua, Fang, Yongjun, Liang, Changda, Ju, Xiuli, Wu, Xuedong, Zhai, Xiaowen, Tian, Xin, Wang, Ningling, Liu, Aiguo, Jiang, Hui, Jin, Runming, Sun, Lirong, Yang, Minghua, Leung, Alex W K, Pan, Kaili, Zhang, Yingchi, Chen, Jing, Zhu, Yiping, Zhang, Hui, Li, Chunfu, Yang, Jun J, Cheng, Cheng, Li, Chi-Kong, Tang, Jingyan, Zhu, Xiaofan, and Pui, Ching-Hon

Published
2021
Full Text
View/download PDF

43. Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Author

Tang, Jingyan, Yu, Jie, Cai, Jiaoyang, Zhang, Li, Hu, Shaoyan, Gao, Ju, Jiang, Hua, Fang, Yongjun, Liang, Changda, Ju, Xiuli, Jin, Runming, Zhai, Xiaowen, Wu, Xuedong, Tian, Xin, Hu, Qun, Wang, Ningling, Jiang, Hui, Sun, Lirong, Leung, Alex W.K., Yang, Minghua, Pan, Kaili, Cheng, Cheng, Zhu, Yiping, Zhang, Hui, Li, Chunfu, Yang, Jun J., Li, Chi-kong, Zhu, Xiaofan, Shen, Shuhong, and Pui, Ching-Hon

Published
2021
Full Text
View/download PDF

45. Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia

Author

Nishii, Rina, Baskin-Doerfler, Rebekah, Yang, Wentao, Oak, Ninad, Zhao, Xujie, Yang, Wenjian, Hoshitsuki, Keito, Bloom, Mackenzie, Verbist, Katherine, Burns, Melissa, Li, Zhenhua, Lin, Ting-Nien, Qian, Maoxiang, Moriyama, Takaya, Gastier-Foster, Julie M., Rabin, Karen R., Raetz, Elizabeth, Mullighan, Charles, Pui, Ching-Hon, Yeoh, Allen Eng-Juh, Zhang, Jinghui, Metzger, Monika L., Klco, Jeffery M., Hunger, Stephen P., Newman, Scott, Wu, Gang, Loh, Mignon L., Nichols, Kim E., and Yang, Jun J.

Published
2021
Full Text
View/download PDF

50. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study

Author

Karol, Seth E, Alexander, Thomas B, Budhraja, Amit, Pounds, Stanley B, Canavera, Kristin, Wang, Lei, Wolf, Joshua, Klco, Jeffery M, Mead, Paul E, Das Gupta, Soumyasri, Kim, Su Y, Salem, Ahmed Hamed, Palenski, Tammy, Lacayo, Norman J, Pui, Ching-Hon, Opferman, Joseph T, and Rubnitz, Jeffrey E

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results